PRESS RELEASE
For Immediate Publication

BIOCON's 9 MONTHS FY 08 REGISTERS GROWTH IN REVENUES & PROFITS POST ENZYMES DIVESTMENT

Revenues Rs. 811 crs : EBITDA Rs. 240 crs : PAT Rs. 160 crs

Bangalore, January, 17th, 2008

Biocon Limited today announced its financial performance for the nine months ended December 31st, 2007.

Note: The discussions in this release reflect the audited financial performance of Biocon Limited based on Indian GAAP on a consolidated basis. This considers the financial performance of Biocon Limited, its wholly owned subsidiaries Syngene International Limited and Clinigene International Limited and its 51% joint venture Biocon Biopharmaceuticals Private Limited.

PERFORMANCE HIGHLIGHTS :

- Consolidated Revenues for the 9 month period, grew by 21% on a comparable basis (after excluding the Enzymes business) over the same period in the previous year.

- Consolidated Operating profits (EBITDA) increased by 20%. Profit after Tax (PAT) rose by 15% .

- Q3 FY 08 registered a one time exceptional pre-tax gain of Rs: 330 crores attributable to the divestment of the Enzymes business.

- Biocon's BIOMAb-EGFR^{TM} received "The Product of the Year 2007" award from Biospectrum.

- Label expansion trials of BIOMAb EGFR commenced for Glioma. Trials for Non Small Cell Lung Cancer will commence shortly.

- Development of Biocon's novel insulin-conjugate for oral delivery (IN-105) is on track. Phase I clamp studies in Sweden nearing completion and Phase II study in India is expected to commence in March 2008.

- Biocon to make a strategic investment in IATRICa Inc., a US based biotech company, to co-develop novel Anti-cancer molecules based on a proprietary immuno-conjugation technology licensed from Johns Hopkins University, USA.

- The Board has agreed in principle to list Syngene, Biocon's wholly owned research services company, on the Indian Stock Exchanges during FY 2008-09. A committee has been established to take the necessary steps. Syngene is a pioneer in contract research and is recognized as among Asia's largest CROs.

- Biocon is continuing its international acquisition efforts

OUTLOOK:

Commenting on the results, **Dr. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited,** said:

"I am pleased that we have sustained both revenue and profit growth post the divestment of our Enzymes business. We continue to increase R&D investments in the firm belief that our innovation led business strategy will deliver rich dividends to our shareholders in the foreseeable future.

An important event this quarter has been the Board's decision to establish a committee to take the necessary steps to list Biocon's wholly owned subsidiary, Syngene on the Indian Stock Exchanges during FY 2008-09. We believe Syngene has attained critical mass that can be leveraged to deliver a strong growth trajectory. As one of Asia's largest and most profitable Contract Research companies, Syngene's IPO can deliver superior shareholder value.

The sale of our enzymes business has put us in a strong financial position to pursue our international acquisition efforts that are aimed at building marketing and distribution capabilities for our range of biologics in the developed markets.

Despite the risk of possible recession in the US and a depreciating dollar, we remain optimistic about delivering continued growth in all our business verticals."

CORPORATE DEVELOPMENTS :

BIOCON TO INVEST IN US BASED BIOTECHNOLOGY COMPANY, IATRICa AND CO-DEVELOP NOVEL IMMUNO-CONJUGATE THERAPEUTICS AGAINST CANCER AND INFECTIOUS DISEASES :

Biocon Limited and IATRICa, Inc. announced a strategic partnership to co-develop an exclusive new class of immuno-conjugates for targeted immunotherapy of cancers and infectious diseases. The companies will co-develop candidate products based upon IATRICa's technology platform and Biocon's proven expertise in drug development, biologics manufacturing and clinical research. IATRICa's technology enables development of a diverse spectrum of immuno-conjugates that are capable of activating potent targeted immune responses against various tumors or pathogens. Biocon will make an equity investment in IATRICa.

IATRICa is a start up biotechnology company formed in 2007 with technology developed at the Johns Hopkins University, Baltimore, Maryland, USA, and has exclusive licenses to the immuno-conjugate technology invented by Johns Hopkins scientists and company founders, Dr. Atul Bedi and Dr.Rajani Ravi. The company is headquartered in Baltimore, Maryland, USA.

BIOMAb EGFR wins BIOSPECTRUM'S "PRODUCT OF THE YEAR" AWARD :

Biocon's flagship oncology product BIOMAb EGFR received The Biospectrum "Product of the Year" award for 2007. The product was chosen for being the first monoclonal antibody to be clinically developed and commercialized in India. Furthermore, Indian patients are amongst the first in the world to have access to this novel drug.

About Biocon

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™. Visit us at www.biocon.com

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Encl: Summarised Consolidated Profit & Loss Statement

For further information contact:

Paula Sengupta

Biocon Limited

Tel: +91 80 2808 2808

Fax: +91 80 2852 3423

Email: paula.sengupta@biocon.com

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT *(Rs. crores)*

Particulars	9M FY 08	9M FY07	Full Year March 31, 2007
INCOME			
Biopharmaceuticals	612	541	741
Enzymes	46	76	109
Contract research	129	90	136
Total Sales	**787**	**707**	**986**
Other income	24	3	4
Total Income / Revenues	**811**	**710**	**990**
EXPENDITURE			
Material & Power Costs	404	406	451
Staff costs	88	65	91
Manufacturing, staff & other exps	79	40	**160**
PBDIT /EBIDTA	**240**	**199**	**288**
Interest and finance charges	8	5	10
PBDT	**232**	**194**	**278**
Depreciation	69	47	67
PBT	**163**	**147**	**211**
Taxes	**7**	**11**	**17**
PROFIT FOR THE PERIOD	**156**	**136**	**194**
Add/(less): Minority interest	4	3	6
Profit Before Exceptional Items	**160**	**139**	**200**
Exceptional Items (Net of Tax)	239	-	
NET PROFIT (PAT)	**399**	**139**	**200**
EPS on issued capital (Rs)- Before Exceptional Item	**16.0**	**13.9**	**20.0**
EPS on issued capital (Rs)- After Exceptional Item	**39.9**	**13.9**	**20.0**

For Immediate Release

BIOCON's H-1 FY '08 DELIVERS 27% PROFIT GROWTH

Revenues at Rs: 553 crores. EBITDA at Rs: 160 crores. PAT at Rs: 107 crores

Bangalore, October 18th, 2007 Biocon Limited today announced its financial performance for the half year ended September 30th, 2007.

Note: The discussions in this release reflect the audited financial performance of Biocon Limited based on Indian GAAP on a consolidated basis. This considers the financial performance of Biocon Limited, its wholly owned subsidiaries Syngene International Limited and Clinigene International Limited and its 51% joint venture Biocon Biopharmaceuticals Private Limited.

PERFORMANCE HIGHLIGHTS:

- Consolidated Revenues grew by 19% over the same period in the previous year. Operating profits (EBITDA) grew by 31%.
- Research Services (Syngene) continued to deliver a robust dollar denominated growth of 60% and an impressive 43% based on Rupee realization. Profit was restrained by rupee appreciation.
- Profit after Tax stood at Rs: 107 crores registering an impressive 27% growth, over the same period in the previous year.
- Biopharmaceuticals and branded formulations showed strong performance. Insulin was a significant contributor.
- Technology and licensing revenues continued to contribute to H-1 financials.
- Biocon announced Phase I human clinical data for its oral Insulin program IN105 at European Association for Study of Diabetes (EASD).
- R&D expenditure increased to Rs: 32 crores from Rs. 19 crores in the previous year.

- **Biocon completed the divestment of its Enzymes division to Novozymes South Asia Private Limited, a wholly owned subsidiary of Novozymes A/S of Denmark for a gross consideration of Rs. 467 crores.**

Outlook

Commenting on the results, **Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited**, said:

"I am pleased to announce the completion of the divestment of our historic enzymes business to Novozymes of Denmark. This provides us with substantial financial resource to consider strategic acquisitions to move up the value chain.

Our branded formulations are rapidly gaining both market share and market leadership. INSUGEN® has already overtaken brand leaders both in some of the domestic market segments as well as a few international markets. BIOMAb EGFR™ has attained market leadership in its very first year of launch in India. Clinical Trials for Glioma and NSCLC have started in order to seek label expansion in these indications. Neo-Biocon has commenced operations in the GCC region which is expected to be a significant market opportunity for Biocon's products. Biocon has also received marketing approval for ABRAXANE® (A nanoparticle albumin bound paclitexel) from DCGI, which will add to the proprietary portfolio of the Oncotherapeutics division.

We continue to be encouraged by the progress being made on the research & development front. Biocon presented Phase I Human Clinical data at the recently held EASD, (European Association for Study of Diabetes), in Amsterdam which was well received.

We are confident that we will continue to deliver growth and profitability despite challenges posed by dollar depreciation and the loss of enzyme income"

CORPORATE DEVELOPMENTS

Biocon completes divestment of enzymes division

Bangalore, October 1st, 2007: Biocon completed the formalities with respect to the divestment of its Enzymes business vertical to Novozymes South Asia Pvt. Ltd., a wholly owned subsidiary of Novozymes A/s of Denmark for USD 115 million today. The post tax proceeds of this divestment will enable Biocon to strategically focus on its core bio-pharmaceuticals business as well as consider key acquisition opportunities to move up the value chain. This divestment will contribute a one time exceptional net gain this fiscal.

Biocon presents Phase I human data at EASD

Bangalore, September 21, 2007: Biocon presented the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam. Phase 1 studies were conducted on healthy volunteers who have been administered IN-105 in the form of a tablet. The human clinical data on IN-105 was presented at the session on Novel therapies. Based on these promising results, Biocon intends to now develop this molecule through further clinical trials.

IN-105 is a novel analog of insulin, proprietary to Biocon. The product has special properties that make it feasible for delivery of Insulin in tablet form, stable at room temperature. The advantages of tablet delivery go beyond the obvious. Besides being needle-free insulin, this

method of delivery allows IN-105 to be delivered into the body in a physiological manner that mimics the way that the pancreas release insulin into the circulation (i.e. into the portal vein). This contrasts with all the other known methods of delivery, including injectable inhaled, buccal and intranasal Insulin.

Biocon receives DCGI marketing approval to launch Abraxane

Bangalore, 18th October 2007: Biocon Limited, India's leading biotechnology company has announced that the company has received the necessary approvals from the DCGI (Drug Controller General of India) to market ABRAXANE® (Nanoparticles based, albumin bound paclitaxel) in India. ABRAXANE® has been approved for use in the treatment of breast cancer and will facilitate affordable access of high-quality supportive care therapy to cancer patients in India.

ABRAXANE® is a product of Abraxis BioScience, Inc. USA. Biocon recently announced a licensing agreement with the company for the commercialization of ABRAXANE® in India. ABRAXANE® uses albumin, a human protein, to deliver paclitaxel unlike the conventional form that uses. chemical solvents, like Cremophors.which are known to cause hypersensitive allergenic reactions. This eliminates the need for pre-medication with steroids or antihistamines. This also reduces infusion time from 3 hours for Cremophor based paclitaxel to just 30 minutes for ABRAXANE®.

The global revenue for ABRAXANE® reached $175 million in the first phase of its launch. Globally ABRAXANE® has shown a positive trend in market penetration for metastatic breast cancer. According to IMS data, for the period between February and September 2006 versus the same period the previous year, there was a 64 percent unit growth in ABRAXANE® versus a 11 percent increase in the overall taxane market.

ABRAXANE® is being clinically studied worldwide in a variety of other oncology settings and currently intends to focus its Phase III trials in first-line metastatic breast cancer, first-line non-small cell lung cancer (NSCLC) and melanoma by developing three Phase III superiority trials using weekly dosing schedules of ABRAXANE®

Shrikumar Suryanarayan joins Scientific Advisory Board

Shrikumar Suryanarayan, relinquished his operational responsibilities as President R&D with effect from 1st October, 2007 and has been inducted to Biocon's Scientific Advisory Board. Dr. Harish Iyer, General Manager R&D has assumed operational responsibility for R&D with effect from 1st October, 2007.

Shrikumar Suryanarayan has been involved with Biocon's R&D division from its inception in 1985 and has contributed to building high value innovation especially with respect to proprietary enzyme technologies including The PlaFractor®. He has been a co-inventor of several patents filed by Biocon over the years and has played a key role in developing the discovery led research initiative for the Company. The company places on record its deep appreciation for his outstanding contribution to building the strong innovation led culture within Biocon's R&D division and for mentoring an excellent team of researchers and technologists, a legacy that will stand Biocon in good stead for the future. The company will continue to benefit from his strategic inputs as a member of its Scientific Advisory Board and looks forward to a long and enduring relationship in the years ahead.

About Biocon

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across 50 countries across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™. Visit us at www.biocon.com

For further information contact:

Paula Sengupta /Gayatri Appaya
Biocon Limited
Fax: +91 80 2852 3423
Fax: +91 80 2558 9125.
Email: paula.sengupta@biocon.com
gayatri.appaya@biocon.com

Manju Lakshmi / Guna Shekar
Brodeur India
Tel: + 91 80 4126 5354
Email: vguna@brodeurindia.com
Email: mpanicker@brodeurindia.com

Disclaimer:

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

NEWS RELEASE - 2

BIOCON LIMITED AND ABRAXIS BIOSCIENCE ANNOUNCE APPROVAL OF ABRAXANE IN INDIA FOR THE TREATMENT OF BREAST CANCER

Bangalore, India and **Los Angeles, Calif (October 18, 2007)** – Biocon Limited, India's leading biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced the approval to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer by the country's Drug Controller General. Commercial introduction of ABRAXANE in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.

"The approval of ABRAXANE for the treatment of breast cancer in India is an important step in providing access to the nab (nanoparticle albumin bound) technology globally," said Patrick Soon-Shiong, M.D., chairman and chief executive officer of Abraxis BioScience. "In partnership with Biocon, we are excited to offer physicians in India this important advance in the treatment of breast cancer."

In August 2007, Biocon and Abraxis announced an agreement for the commercialization of ABRAXANE in India by Biocon. Under the terms of the agreement, Biocon will have the right to market ABRAXANE in India, Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia, Kuwait and certain other South Asian and Persian Gulf countries.

Abraxis BioScience will be initiating a worldwide head-to-head Phase III registration trial comparing weekly ABRAXANE to every three week Taxotere for the treatment of first-line metastatic breast cancer as well as Phase III trials for the treatment of non-small cell lung cancer and melanoma. ABRAXANE is currently under active review in Australia, Russia, China and the European Union by their respective regulatory agencies.

Kiran Mazumdar Shaw, chairman and managing director, Biocon Limited said, “This is a significant step for Biocon’s innovation led Oncotherapeutics division in our endeavor to bring new therapeutics for Indian cancer patients. There is a huge need for ABRAXANE in the treatment of breast cancer in the country and we look forward to attaining market leadership in this segment.”

ABRAXANE is an important addition to Biocon’s Oncotherapeutics portfolio which has already seen the successful launch of its proprietary antibody, BIOMAb EGFR for the treatment of head and neck cancers.

The approval of ABRAXANE in India was based on the clinical trial data that was the basis of approval in the United States. In that trial, ABRAXANE demonstrated a superior response rate with an almost doubling of the reconciled target lesion response rate when compared with Taxol® in a prospectively randomized trial of 460 patients with metastatic breast cancer.

ABRAXANE uses albumin, a human protein, to deliver the active ingredient paclitaxel. Unlike other chemotherapy treatments, ABRAXANE does not contain chemical solvents which eliminates the need for pre-medication with steroids or antihistamines often needed to prevent the toxic side effects associated with solvents. ABRAXANE is administered in 30 minutes (as compared to three hours for solvent-based paclitaxel).

About ABRAXANE

The U.S. Food and Drug Administration approved ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis and renal dysfunction. For the full prescribing information for ABRAXANE, please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis and AstraZeneca Pharmaceuticals LP.

About Biocon Limited

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global

marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™;. Visit us at www.biocon.com

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab™ platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE®, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

Forward-Looking Statement

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding its planned clinical trials. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the fact that results from pre-clinical studies may not be predictive of results to be obtained in the clinical trial, delays in commencement and completion of the clinical trial, including slower than anticipated patient enrollment and adverse events occurring during the clinical trial, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Taxol® is a registered trademark of Bristol-Myers Squibb company.

Abraxis BioScience Contact:
Investors and Media:
Christine Cassiano, (310) 633-9495

Biocon Limited Contact:
Paula Sengupta/ Gayatri Appaya
20th K.M – Hosur Road,
Electronic City P.O.,
Bangalore 560 100
Tel: +91 80 2808 2808
Fax: +91 80 2852 3423
Email: paula.sengupta@biocon.com
gayatri.appaya@biocon.com

Manjulakshmi/Guna Shekar
Tel: +91 80 4126 5354
Email : mpanicker@brodeurindia.com
vguna@brodeurindia.com

# # #

Press Release - 3

Kiran Mazumdar-Shaw awarded the 'Veuve Clicquot Initiative For Economic Development For Asia'

Bangalore, October 16, 2007: Ms. Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon Limited has been honoured with the 'Veuve Clicquot Initiative For Economic Development For Asia' award. The award for Economic Development was introduced for the first time in 2007. There were three Economic Development awards that went to three women from Asia (India) Latin America (Bolivia) and Africa (Algeria). This is a special award that looks beyond business success to CSR and a combined effort to bring about economic change in developing economies. Ms. Kiran Mazumdar-Shaw has been nominated as the very first winner for Asia. Ms. Shaw was presented the award at Reims, one hour away from Paris over a unique two-day function.

Started in 1972, the Veuve Cliquot Business Woman Award was created to pay lasting tribute to one of the world's greatest businesswomen, probably the very first one, Madame Clicquot. The award celebrates special women who have demonstrated undisputable business success, clear strategic vision, entrepreneurship, daring vision and unique leadership skills, providing them wide recognition within their business sector as well as the media.

Highly prized, it is the first and original award for women in business life. In its 35th year, the Award was founded to celebrate the memory of Madame Clicquot, who created the Champagne House that bears her name. Her audacity, bravery and creativity are celebrated each year, in the light of the finalists whose achievements, in their turn, present role models for women aspiring to take their place in the business world.

Past winners represent some of the most famous women in business: Dame Marjorie Scardino; Dame Anita Roddick; Ms Dianne Thompson; Mrs Ann Gloag; Ms Linda Bennett. Last year's winner was Vivienne Cox,Executive Vice President & CEO , BP Gas.

About The Veuve Clicquot Ponsardin Champagne House

The Veuve Clicquot Ponsardin Champagne House in France was founded in 1772 and bears the name of an exceptional woman ("veuve" meaning "widow" and "Ponsardin" was her maiden name who lived and ran the company in the XIXth century. The company is totally dedicated to produce this prestigious wine and promote it all over the world.

About Biocon

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™.

For further information please contact:

Biocon Limited Contact:
Paula Sengupta/ Gayatri Appaya
20th K.M – Hosur Road,
Electronic City P.O.,
Bangalore 560 100
Tel: +91 80 2808 2808
Fax: +91 80 2852 3423
Email: paula.sengupta@biocon.com
gayatri.appaya@biocon.com

Manjulakshmi/Guna Shekar
Tel: +91 80 4126 5354
Email: mpanicker@brodeurindia.com
vguna@brodeurindia.com

Press Release - 4

FOR IMMEDIATE RELEASE

Biocon Limited presents human clinical data on IN-105 (oral insulin) at the EASD meeting in Amsterdam.

Bangalore, September 21, 2007: Biocon Limited, India's premier biotechnology company announced that the company has presented the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam today. Phase 1 studies were conducted on healthy volunteers who have been administered IN-105 in the form of a tablet. The human clinical data on IN-105 was presented at the session on Novel therapies. Based on these promising results, Biocon intends to now develop this molecule through further clinical trials.

IN-105 is a novel analog of insulin, proprietary to Biocon. The product has special properties that make it feasible for delivery in tablet form stable at room temperature. The advantages of tablet delivery go beyond the obvious. Besides being a needle-free insulin, this method of delivery allows IN-105 to be delivered into the body in a physiological manner that mimics the way that the pancreas release insulin into the circulation (i.e. into the portal vein). This contrasts with all the other known methods of delivery, including inhaled insulin, which brings in insulin from the periphery into the circulation.

Ms. Kiran Mazumdar Shaw, CMD, Biocon Limited said, "This is indeed an encouraging step towards our efforts of bringing an oral insulin to diabetic patients across the world. IN-105 promises to be a significant value differentiator in Biocon's quest for global leadership in the insulin segment."

Biocon Limited has carried out all of the development for this molecule, including clinical development at its facilities in Bangalore, India. It has also recently obtained approval from the Swedish medical authorities to carry out Phase 1 human clamp studies for this molecule in Sweden. This will be the first such clinical trial outside of India for IN-105. The Swedish trial will be carried out at the Karolinska Institute clinical research unit and will be focused on obtaining more pharmacological understanding of the mode of action of IN-105.

About Biocon

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes.

With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™.

For further information please contact:

Biocon Limited Contact:
Paula Sengupta/ Gayatri Appaya
20th K.M – Hosur Road,
Electronic City P.O.,
Bangalore 560 100
Tel: +91 80 2808 2808
Fax: +91 80 2852 3423
Email: paula.sengupta@biocon.com

Manjulakshmi/Guna Shekar
Tel: +91 80 4126 5354
Email : mpanicker@brodeurindia.com
vguna@brodeurindia.com

Press Release - 5

News Release

BIOCON LIMITED AND ABRAXIS BIOSCIENCE ANNOUNCES LICENSING AGREEMENT FOR THE COMMERCIALIZATION OF ABRAXANE IN INDIA

Bangalore/Los Angeles – (August 09, 2007) – Biocon Limited, India's leading biotechnology company and Abraxis BioScience,Inc.(NASDAQ ABBI), an integrated, global biopharmaceutical company, today announced a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the terms of the agreement, Biocon will also have the right to market ABRAXANE in Pakistan, Bangladesh, Sri Lanka, United Arab Emirates, Saudi Arabia, Kuwait and certain other Persian Gulf countries. As part of this agreement, Abraxis will receive royalties from Biocon based on net sales of ABRAXANE in these countries.

"ABRAXANE adds tremendous value to our innovation led Oncotherapeutics marketing strategy. Biocon is committed to bringing new therapeutics for the benefit of patients both in India and other regions of the world through in-house and licensed products. Our partnership with Abraxis on multiple fronts is enabling us to realize this objective in an effective and expedious manner said Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon Limited. "

In July 2007, Abraxis submitted to India's Ministry of Health and Family Welfare an application to market ABRAXANE for the treatment of breast cancer.

"This agreement is an important step in the development of a global commercialization framework that incorporates unique country-by-country needs," said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience. "Importantly, we are pleased that this partnership with Biocon affords us the opportunity to bring ABRAXANE, an portant advance in chemotherapy, to these countries."

About ABRAXANE®

The U.S. Food and Drug Administration approved ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for

ABRAXANE®, please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis and AstraZeneca Pharmaceuticals LP.

About Biocon Limited

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™. Visit us at www.biocon.com

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its *nab*™ platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this *nab* platform, ABRAXANE®, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com .

FORWARD-LOOKING STATEMENT

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the development of the licensed intellectual property portfolio. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward- looking statements. The development of the licensed intellectual property portfolio could be affected by a number of factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Abraxis BioScience Contact:
Christine Cassiano (310) 405-7417

Biocon Contact:
Investors and Media:
Paula Sengupta / Gayatri Appaya
Biocon Limited Tel: +91 80 2808 2808
Email: paula.sengupta@biocon.com,
gayatri.appaya@biocon.com

Press Release - 6

FOR IMMEDIATE PRESS RELEASE
Monday, July 30, 2007
PHARMA – BIOTECH ALLIANCE

Neobiocon established in Dubiotech

- Biocon and Neopharma signed an MOU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.

- The new venture expands Biocon's global network to provide affordable bio-therapeutics for unmet medical needs.

- Through this joint venture Neopharma takes a humble step towards the realization of the vision of the Father of the Nation, Late HH Sheikh Zayed Al Nahyan – 'Health for All'.

- On the anvil are specialty bio-pharmaceutical products for life threatening diseases.

Indian Biotechnology major, Biocon Limited and Abu Dhabi based pharmaceutical manufacturer Neopharma announced today the setting up of Neobiocon.

Established at Dubai Biotechnology and Research Park (Dubiotech) in Dubai, this JV company will provide affordable life saving drugs to the people of the UAE. Neobiocon is a pioneering initiative that heralds the region's first foray to develop and market life saving biopharmaceutical niche products in key therapeutic areas such as oncology, diabetes, auto-immune disorders, cardiology, anti-obesity drugs and new generation immunosuppressant drugs.

Neobiocon will take initiatives to educate people on the debilitating effects of lifestyle diseases by rolling out educational campaigns through physician workshops. There will be a dual approach of local development coupled with educational programs/workshops that will benefit the local population.

The Dubai Biotechnology and Research Park (Dubiotech) provides infrastructure to various companies to set up their own establishments apart from offering readymade offices for R&D, pilot production and storage facilities. Dubiotech helps bridge research, education and industry through national and international collaboration.

Speaking on the announcement, **Ms. Kiran Mazumdar-Shaw,** CMD, Biocon Limited said, "The establishment of Neobiocon takes our recently announced JV with Neopharma a step further. This in fact is a continuation of our tie-up. We are delighted to be able to provide the advantage of Biocon's proprietary biotech and other related biopharmaceutical pipeline products to the people in this region. Our long term vision is to ensure that the country is self-sufficient in terms of biopharmaceutical products."

Dr. B R Shetty, MD & CEO, Neopharma remarked, "It gives us immense pleasure and great honour to join hands with biotech major, Biocon, and pioneer the introduction of world-class pharmaceutical biotech products, right here in the heart of the Emirates. Ms.Kiran Mazumdar -Shaw has taken Biocon from an enzyme manufacturing company to a Biotech Powerhouse.

Added Mr. Rakesh Bamzai, President, Marketing, Biocon Limited, "Neobiocon will be committed to developing a range of products for debilitating disease segments. Obesity, Diabetes, hypertension and high levels of cholesterol are interlinked and go hand-in-hand. Biocon's research addresses all

these segments. Neobiocon will offer products that cater to lifestyle disorders and oncology. We will also produce immunosuppressant drugs. "

Biotherapeutics for cardiovascular diabetes and oncology segments represent the fastest growing class of drugs in the $5 billion GCC (Gulf Cooperation Council) pharmaceutical market.

Studies have revealed high mortality rates due to diabetes and cardiovascular disorders in this region. Disease incidence is also alarmingly high. In addition to India and sub-Saharan Africa, the greatest relative increase of these diseases will occur in the Middle Eastern Countries. Obesity is also a common, serious and growing problem. Current epidemiological estimates suggest that 1.1 billion people worldwide are above their ideal weight. Developing obesity treatments that target novel pathways is a growing focus for biopharmaceutical companies.

The biotech product offerings include Biologicals, proprietary/In-licensed products, targeted therapeutics; research based differentiated formulations and innovative drug delivery system. NeoBiocon shall be targeting innovative products. Besides the UAE, the Dubai office will represent the company in Saudi Arabia, Kuwait, Bahrain, Qatar and Oman.

Neobiocon's product mix aims to cater to these categories of patients. Adds Dr. B R Shetty, "For the doctors and patients here, this would mean access to world class biopharmaceuticals at affordable prices".

Neobiocon's platform emerges from a symbiotic partnership between the two companies. Biocon's knowledge base & cutting-edge technology and Neopharma's manufacturing prowess & local expertise will complement each other.

About Neopharma

Neopharma is Abu Dhabi's premier pharmaceutical manufacturing company. In less than 3 years, this world class facility has already introduced more than 70 formulations including antibiotics, pain killers, anti allergics and drugs in cardiology and diabetology segments. The company's ability to introduce new products in quick succession stems for a cohesive team work. A robust product research and development team, hi-tech manufacturing, quality embedded operations and skill regulatory support go hand in hand for one purpose – World class quality pharmaceuticals.

The company's efforts are receiving valuable recognition. The company already ranks amongst the top 15 companies in UAE and is the proud recipient of the prestigious Mohammed bin Rashid Al Maktoum Award for the manufacturing category. Besides approval in the Ministry of Health, UAE and the GCC, Neopharma has received the Current European Union Good Manufacturing Practice Certificate from Belgium. All these reflect Neopharma's penchant for quality – a key driver for generic pharmaceutical products.

A planned foray into European markets, work on nanotechnology based products and a joint venture with Biocon to herald the region's premier facility to develop life saving biotech and biopharmaceutical products are key agenda in the near future. Besides, the company facility is being recognised as a regional contract manufacturing hub for large companies such as Apotex, Canada and many European companies. Domestic market will continue to be in the limelight and Neopharma is poised to introduce several products to strengthen presence across more therapeutic categories.

For more information about Neopharma, please consult www.neopharma.ae

Contact Address

Post Box: 72900, Abu Dhabi, United Arab Emirates Tel: +971 2 550 1000 Fax: +971 2 550 1199
Email: neopharma@neopharma.ae

About Biocon

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR.

For more information about Biocon, please consult www.biocon.com.

Biocon Limited Contact:
Paula Sengupta/ Gayatri Appaya
20th K.M – Hosur Road,
Electronic City P.O.,
Bangalore 560 100
Tel: +91 80 2808 2808
Fax: +91 80 2852 3423
Email: paula.sengupta@biocon.com
gayatri.appaya@biocon.com

Manjulakshmi/Guna Shekar
Tel: +91 80 4126 5354
Email : mpanicker@brodeurindia.com
vguna@brodeurindia.com

Press Release - 7

Immediate Release

ABRAXIS BIOSCIENCE AND BIOCON LIMITED ANNOUNCE LICENSING AGREEMENT FOR G-CSF IN NORTH AMERICA AND THE EUROPEAN UNION

Bangalore India/LOS ANGELES, Calif., (July 19, 2007) –Biocon Limited, India's leading biotechnology company and Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union. Under the terms of the agreement, Biocon will receive an upfront licensing fee and, following approval in the licensed territories, royalties from Abraxis BioScience. Detailed financial terms of the agreement were not disclosed.

"Abraxis Bioscience is an ideal partner for Biocon as we increase our focus on oncology. We are confident that both partners will realize success in attaining market leadership for G-CSF in their respective markets," said **Kiran Mazumdar-Shaw, chairman and managing director of Biocon Limited.** "The present licensing arrangements will certainly pave the way to other opportunities in the foreseeable future."

G-CSF is an haematopoietic growth factor that works by encouraging the bone marrow to produce more white blood cells. Therapeutic G-CSF is primarily used for the treatment of neutropenia, the lowering of the white blood cells that fight infections. Biocon has received regulatory approval from the Indian DCGI for the treatment of neutropenia in cancer patients and intends to launch the product in India through its Oncotherapeutics division.

"We are very excited to enter into this collaboration with Biocon. We believe that this partnership allows us to participate in the emerging biosimilars market and build a new platform for growth." said **Patrick Soon-Shiong, M.D., chairman and chief executive officer of Abraxis BioScience.**

"We believe that this collaboration will facilitate affordable access of high-quality supportive care therapy to cancer patients across the world," said Dr. Subir Basak, general manager, Business Development & Oncotherapeutics SBU Head, Biocon Limited.

The biological activity of Biocon's G-CSF used in clinical trials was evaluated by NIBSC (National Institute of Biological Standards and Control), UK, which provides

independent testing of biological medicines. The NIBSC found that the potency of Biocon's drug met the necessary requirements of a biosimilar G-CSF.

About Biocon Limited

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™. Visit us at www.biocon.com

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its *nab*™ platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this *nab* platform, ABRAXANE®, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com .

FORWARD LOOKING STATEMENT

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the development of the licensed intellectual property portfolio. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward looking statements. The development of the licensed intellectual property portfolio could be affected by a number of factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained

in this press release as the result of new information or future events or developments.

Abraxis BioScience Contact:
Investors and Media: Christine Cassiano (310) 405-7417

Biocon Contact:
Paula Sengupta / Gayatri Appaya
Biocon Limited Tel: +91 80 2808 2808
Email: paula.sengupta@biocon.com
gayatri.appaya@biocon.com

Press Release - 8

BIOCON TO FOCUS ON BIOPHARMACEUTICALS, DIVESTING ENZYMES FOR USD 115 MILLION TO NOVOZYMES

- Agreement to divest Enzymes business for USD 115 million to NOVOZYMES
- Biocon business portfolio focused on bio-pharmaceuticals

Bangalore, July 18, 2007:

Biocon announced today a definitive agreement to divest its Enzymes business vertical to Novozymes A/S for USD 115 million. This will enable Biocon to strategically focus on its core bio- pharmaceuticals business. The enzyme business includes a broad range of industrial enzymes, food additives and process aids. This transaction, subject to shareholder and regulatory approvals, is expected to be completed by the end of the 3rd quarter of CY 2007.

Upon the completion of this divestment, Biocon will concentrate its activities on its bio-pharma business verticals that include APIs, biologicals and proprietary molecules both commercialized and under development.

Announcing the new development, Ms. Kiran Mazumdar-Shaw, CMD, Biocon Limited said: “Over the past decade we have clearly recognized the high growth trajectory of our bio-pharma business verticals and have progressively invested to build proprietary know-how and global scale. We believe that this is the right time to divest our enzymes business and focus on unleashing the full potential of our Bio-pharma businesses.

Novozymes as the recognized world leader in enzymes will be in a strong position to leverage our existing enzymes portfolio built over a span of nearly 3 decades. “

Steen Riisgaard, CEO of Novozymes said “The acquisition of Biocon’s enzyme business provides an important step for Novozymes in strengthening our position in the Indian market, which we believe has an attractive growth potential. The activities of Biocon have an excellent strategic fit to our existing enzyme business. We see several interesting and synergistic market opportunities making this a very interesting acquisition”.
Biocon’s enzyme business will be integrated into Novozymes South Asia Pvt. Ltd., a fully owned affiliate of Novozymes A/S. Production and formulation will continue at the Biocon site under lease and service agreements with Novozymes.

Biocon’s Board of Directors unanimously recommended the sale, subject to certain limited conditions normal in a transaction of this nature including the approval of Biocon’s shareholders.

The agreement has been signed on July 18, 2007 and will seek shareholders approval by postal ballot to be initiated shortly. The two companies expect the business transfer agreements to be approved by appropriate authorities and the transaction is expected to be closed before the end of Q3 CY 2007.

Allegro Capital Advisors acted as Biocon's investment bankers to the transaction.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace. Read more at www.novozymes.com

About Biocon
Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd. and Clinigene International Ltd. form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Many of these products have USFDA and EMEA acceptance. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb EGFR™.

For further information please contact:

BIOCON
Paula Sengupta/ Gayatri Appaya
Tel: +91 80 28082808
Fax: +91 80 2852 3423
Email: paula.sengupta@biocon.com
gayatri.appaya@biocon.com

NOVOZYMES
Johan Melchior
Phone (direct): +45 4446 0690
Phone (mobile): +45 3077 0690